JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB183223

Recombinant Human PACT (PKR activating protein) / PRKRA

Be the first to review this product! Submit a review

|

(0 Publication)

Recombinant Human PACT (PKR activating protein) / PRKRA is a Human Full Length protein, in the 1 to 313 aa range, expressed in Escherichia coli, with >80%, suitable for SDS-PAGE, Mass Spec.

View Alternative Names

PACT, RAX, HSD-14, HSD14, PRKRA, Interferon-inducible double-stranded RNA-dependent protein kinase activator A, PKR-associated protein X, PKR-associating protein X, Protein activator of the interferon-induced protein kinase

1 Images
SDS-PAGE - Recombinant Human PACT (PKR activating protein) / PRKRA (AB183223)
  • SDS-PAGE

Supplier Data

SDS-PAGE - Recombinant Human PACT (PKR activating protein) / PRKRA (AB183223)

15% SDS-PAGE analysis of ab183223 (3μg).

Key facts

Purity

>80% SDS-PAGE

Expression system

Escherichia coli

Tags

His tag N-Terminus

Applications

Mass Spec, SDS-PAGE

applications

Biologically active

No

Accession

O75569

Animal free

No

Carrier free

No

Species

Human

Storage buffer

pH: 8 Constituents: 50% Glycerol (glycerin, glycerine), 1.17% Sodium chloride, 0.32% Tris HCl, 0.03% (R*,R*)-1,4-Dimercaptobutan-2,3-diol, 0.03% EDTA

storage-buffer

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "SDS-PAGE": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" }, "Mass Spec": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }

Sequence info

[{"sequence":"MGSSHHHHHHSSGLVPRGSHMGSMSQSRHRAEAPPLEREDSGTFSLGKMITAKPGKTPIQVLHEYGMKTKNIPVYECERSDVQIHVPTFTFRVTVGDITCTGEGTSKKLAKHRAAEAAINILKANASICFAVPDPLMPDPSKQPKNQLNPIGSLQELAIHHGWRLPEYTLSQEGGPAHKREYTTICRLESFMETGKGASKKQAKRNAAEKFLAKFSNISPENHISLTNVVGHSLGCTWHSLRNSPGEKINLLKRSLLSIPNTDYIQLLSEIAKEQGFNITYLDIDELSANGQYQCLAELSTSPITVCHGSGISCGNAQSDAAHNALQYLKIIAERK","proteinLength":"Full Length","predictedMolecularWeight":"36.8 kDa","actualMolecularWeight":null,"aminoAcidEnd":313,"aminoAcidStart":1,"nature":"Recombinant","expressionSystem":"Escherichia coli","accessionNumber":"O75569","tags":[{"tag":"His","terminus":"N-Terminus"}]}]

Properties and storage information

Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle
False

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

PACT also known as PKR activating protein or PRKRA is a regulator of the protein kinase R (PKR). This protein plays a role in PKR activation stimulating its autophosphorylation. Structurally PACT has a molecular mass of approximately 37 kDa. Researchers observed its expression in many tissues with notable presence in the brain and in immune cells. PACT functions interact with PKR and it also goes by the alternative names PKR activator and PKR protein activator.
Biological function summary

PACT involves in the cellular stress response signaling. It serves as an activator for PKR a kinase that becomes active during viral infections and stress. PACT forms complexes with PKR facilitating its activation and subsequent initiation of downstream signaling cascades. It contributes significantly to the regulation of protein synthesis and cell growth by modulating these pathways. In conditions of stress PACT ensures adequate PKR activation for host defense.

Pathways

PACT is key in the interferon signaling pathway and the stress response pathway. It partners with PKR to suppress protein synthesis through phosphorylation of the eukaryotic initiation factor 2 alpha (eIF2α) which slows down protein production during cellular stress. This interaction places PACT at a junction of antiviral defense and stress adaptation with PKR serving as an essential protein involved in these pathways.

PACT links to conditions such as Huntington’s disease and dystonia. Dysregulation in PACT's function impacts these neurodegenerative disorders as it relates to its role in stress response. Altered interactions between PACT and PKR contribute to neuronal dysfunction highlighting its importance in these pathologies. Understanding how PACT and its partner proteins like PKR and eIF2α operate can lead to potential therapeutic targets for these diseases.

Specifications

Form

Liquid

Additional notes

ab183223 was purified using conventional chromatography techniques.

General info

Function

Activates EIF2AK2/PKR in the absence of double-stranded RNA (dsRNA), leading to phosphorylation of EIF2S1/EFI2-alpha and inhibition of translation and induction of apoptosis. Required for siRNA production by DICER1 and for subsequent siRNA-mediated post-transcriptional gene silencing. Does not seem to be required for processing of pre-miRNA to miRNA by DICER1. Promotes UBC9-p53/TP53 association and sumoylation and phosphorylation of p53/TP53 at 'Lys-386' at 'Ser-392' respectively and enhances its activity in a EIF2AK2/PKR-dependent manner (By similarity).

Sequence similarities

Belongs to the PRKRA family.

Post-translational modifications

Phosphorylated at Ser-246 in unstressed cells and at Ser-287 in stressed cells. Phosphorylation at Ser-246 appears to be a prerequisite for subsequent phosphorylation at Ser-287. Phosphorylation at Ser-246 and Ser-287 are necessary for activation of EIF2AK2/PKR under conditions of stress.

Product protocols

Target data

Activates EIF2AK2/PKR in the absence of double-stranded RNA (dsRNA), leading to phosphorylation of EIF2S1/EFI2-alpha and inhibition of translation and induction of apoptosis. Required for siRNA production by DICER1 and for subsequent siRNA-mediated post-transcriptional gene silencing. Does not seem to be required for processing of pre-miRNA to miRNA by DICER1. Promotes UBC9-p53/TP53 association and sumoylation and phosphorylation of p53/TP53 at 'Lys-386' at 'Ser-392' respectively and enhances its activity in a EIF2AK2/PKR-dependent manner (By similarity).
See full target information PRKRA

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com